Nodular lymphocyte predominance Hodgkin's disease (NLPHD) is characterized by the presence of atypical putatively neoplastic cells (L &H
ODULAR LYMPHOCYTE predominance Hodgkin's disease (NLPHD) exhibits many features that distinguish it from other subtypes of Hodgkin's Clinically, NLPHD is very indolent and can remain stable for years, even without treatment.3s4 Histologically, the disease is characterized by the presence of the putative tumor cells, L & H (lymphocytic and histiocytic) cells, which have been shown to have a B-cell Although NLPHD is now generally accepted as a B-cell disorder, whether it represents a true neoplasm or merely a reactive or premalignant condition remains unresolved. A proportion of patients with NLPHD develop large cell B lymphoma (LCL), and it is often assumed, although not proved, that the lymphoma is clonally linked to the NLPHD.739"2 Numerous attempts have been made to verify the neoplastic nature of NLPHD by demonstration of monoclonality using immunohistochemical or molecular-genetic techniques. Analyses for Ig light chain protein and mRNA expression in L & H cells by immunostaining and in situ hybridization have yielded heterogeneous results, ranging from absence of expression to polyclonal or monoclonal expression of light chain protein or mRNA.5.13-17 Investigations for monoclonal rearrangements of Ig genes using Southern blot or polymerase chain reaction (PCR) analysis have not proved fruitful in most However, in two recent investigations using an improved PCR method and a single cell isola- 
MATERIALS AND METHODS
Tissue samples. Paraffin-embedded blocks or unstained tissue sections from 33 cases of NLPHD were retrieved from the surgical files of the Histopathology Department, University College London Medical School. Fifteen of the 33 NLPHD cases had complicating high grade B-cell lymphomas (LCL), five of which developed simultaneously, five developed 1 to 5 years after diagnosis of NLPHD (including cases 3 and 4) and 5 after more than 10 years (including cases one and two). Hematoxylin and eosin stained sections of all cases were available for histological review.
Immunostaining. Four-micron tissue sections were cut. After dewaxing, the sections were heated in a pressure cooker or a microwave oven to retrieve antigenicity and immunostaining was performed as previously Whenever possible, depending on availability of adequate tissue in the blocks, sections were stained with antibodies to Ig kappdambda, CD20, CD79a, CD3, and CD21 (Dako, High Wycombe, UK).
Microdissection and DNA preparation. Microdissection was performed as previously described.* of the same section were microdissected by a drawn-out glass pipette in the presence of 20% ethanol under a microscope (Fig 1) . 
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Case 4 : gcgagagggg gggatClTAC-GGATActgta gtggtggtatctattgttctgtctttgacta Sequences between the FR3 and VWH primer regions of rearranged Ig VH genes amplified from LCL are shown. Oligonucleotide sequences taken from the deduced unique N regions that were selected as targets for CSP are shown in bold capitals. The entire sequences of all the selected clones are available on request from the corresponding author.
at 37°C for 1 hour. The klenow enzyme was inactivated at 68°C for 10 minutes, and the PCR products were purified using Wizard PCR prekit (Promega Ltd, Southampton, UK). Cloning of the PCR products was performed using predigested Lambda Fix11 Vector Cloning kit (Stratagene Ltd, Cambridge, UK). Clones containing fragments of the appropriate size were screened with PCR. Positive clones were sequenced using Sequenase PCR Product Sequencing kit (USB, Cleveland, Ohio) following the manufacturer's instructions.
Clone specijic primer design and PCR amplijication. Clone specific primers (CSP) were designed using the unique complementarity determining region (CDR) I11 sequences centered on N regions of four LCL cases (sequences of rearranged IgVH regions from LCL cases 1 through 4 are shown in Table 1 .) Suitability of primers for PCR was confirmed using the Fasta program in the GCG software package (Madison, WI). Clone specific primers were used with FR2 (cases 1 and 4) and FR3 primer (cases 1 through 4) and each optimized for specific amplification of the relevant LCL (Table 2) . Sensitivity relative to consensus PCR was estimated using specific LCL DNA diluted with polyclonal DNA extracted from hyperplastic tonsil (see Table 2 and Fig 3) and specificity determined using non-LCL lymphoid DNA as template. Optimized clone specific PCR was applied to at least 10 aliquots of DNA extracted from complete sections of preceding NLPHD and from microdissected L & H cells in each case. (Fig 1) . In eighteen of the 33 cases, there was sufficient material for immunostaining of Ig light chains, and kappa light chain restriction was demonstrated in the L & H cells of 11 cases. Staining in six cases was not satisfactory. One case was negative for both kappa and lambda light chains. All 15 LCLs showed staining with CD20 and CD79a. Four showed kappa light chain restriction, and staining of three cases was unsatisfactory. Eight cases were not stained for light chains due to shortage of material.
RESULTS
Histology
PCR ampliJication with consensus primers. Using m 3 1 JH primers, all extracts from 33 complete NLPHD sections and microdissected L & H cells from 12 cases of NLPHD gave rise to a smear or variable ladder of PCR products. With FR2/JH primers a smear or ladder of products was seen in 16 (including cases 1 through 4) of the 25 NLPHD cases, whereas nine were not amplifiable. Thus, no monoclonal populations of B cells were detected in the NLPHD samples. Of 15 cases of LCL, eight gave rise to a reproduc- ible dominant band when amplified using FR3/JH primers, four (cases 1 through 4) of which showed a dominant band using FR2/JH. The remaining seven cases showed a smear of PCR products. Thus, monoclonality was confirmed in 53% of LCL cases. Comparison of PCR products from the LCL cases with those from the corresponding cases of NLPHD, including microdissected L & H cells showed no matching dominant bands to the clone in the LCLs (Fig 2) . PCR reactions with water (no template) and samples from microdissected T-cell populations and washings showed no products, whereas the positive control gave rise to the expected dominant band in each reaction.
Cloning and sequencing. IgVH PCR products (cases 2 through 4 from FR2 to JH region; case 1 from FR3 to JH region) from four cases of LCL were cloned. At least six clones from each case were sequenced. Sequence analysis showed that all clones contained combinations of variable (V), diversity (D), and joining (J) fragments and had a variable number of N nucleotides at the V-D (Nl) and D-J (N2) junctions (Table 1) . None of the N region sequences from any one case was similar to those from other cases or showed high homology to any sequence in the GCG gene database. The three cases amplified from FR2/JH were analyzed for VH usage and all found to belong to the VH3-7 family. When compared with germ line sequences, several silent and replacement mutations were identified in CDRII and FR3 in all cases. In case 4, some mutations were common to all the clones, but others varied. These intraclonal variations may indicate ongoing mutations in the tumor.
Clone specific PCR. All four clone specific primers, in conjunction with FR2 or FR3 primer, gave rise to products of the predicted size when applied to the specific LCL extract, but no products were seen from other lymphoid tissue samples. Efficiency of clone specific detection varied between cases and different framework primers (Table 2) . Us-
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Fig 3. Sensitivity of detection of tumor clone from case 4 diluted with polyclonal tonsillar DNA using consensus primers (FR3IJH 10% gel; top) and clone specific amplification (FR2/CSP 6% gel; bottom). 1, 50% tumor extract; 2, 5%; 3, 0.5%; 4, 0.05%; and 5, 0.005%.
ing FR2 with the clone specific primers, sensitivities of specific PCR increased by five (case 1) to 100 (case 4) times, when compared with consensus PCR (Fig 3) . Using FR3 as the second primer, the sensitivities ranged from identical (case 4) to 1,000 times more sensitive. No products were seen using CSP on extracts of complete sections or microdissected L & H cells from NLPHD, which preceded specific LCL (Fig 4) . Such a rate should not be sufficient to totally abolish PCR amplification of the VH region of four cases. Furthermore, the inclusion of thymidine at the 3' end of the clone specific primers makes them more tolerant to mismatch at the 3' end.3y Therefore, the most probable explanation of our negative clone specific PCR results in NLPHD is that the tumor clones were not present or were extremely rare in that phase of the disease. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From investigation, no dominant clones were detected in NLPHD using consensus primers, whereas five of the LCL showed a dominant band. In contrast to our results, clone-specific primers derived from LCL CDRIII regions confirmed the presence of the LCL clone in the NLPHD in two cases. We have now used clone-specific PCR to analyze an additional two cases, one of which shows no evidence of the LCL tumor sequence in the NLPHD and in the other we have amplified fragments of the appropriate size from 2 of 73 aliquots (each containing an estimated 10 to 100 ng of DNA) of the NLPHD extract. We are currently evaluating this result by sequencing of products. If the specificity of the products is confirmed, in the light of the results of Wickert et these findings would suggest that LCL clones may be present during the NLPHD phase of the disease as minor subsets of polyclonal L & H cell populations.
